Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. - Wikidata - awgldk - TriplyDB

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

http://www.wikidata.org/entity/Q34274190

about

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Review of vancomycin-induced renal toxicity: an update Advances in antibiotic therapy in the critically ill Pseudomonas aeruginosa ventilator-associated pneumonia management Burn wound healing and treatment: review and advancements Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Estimation of creatinine clearance using plasma creatinine or cystatin C: a secondary analysis of two pharmacokinetic studies in surgical ICU patients Antibiotic stewardship in the intensive care unit.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?Outcome Assessment of Critical Care Pharmacist Services Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.Vancomycin-associated renal dysfunction: where are we now?Safety issues and drug-drug interactions with commonly used quinolones.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Impact of special patient populations on the pharmacokinetics of echinocandins.Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.

P2860

Q26739860-4F60225F-72B7-410D-A81E-F2CBF4576C7F Q26746932-DE71F22B-3A92-4E08-9AD8-7E91FC62E6C4 Q26749328-070CE2D1-D3BB-4731-B6EB-833EC55B1736 Q26768365-379FCF10-706A-47ED-86AC-DF5E22D0F7E9 Q27013939-010CAAB9-2BE3-4958-8DE4-894D9D462456 Q28080607-3686E7A1-3BF8-4C39-88EB-67628E53D883 Q30238578-F8644CF1-8E20-489E-8AE5-F63AEDB6DE3A Q30249512-9B983A94-7E5A-41F5-BDB1-2DD67682B5C9 Q30316322-17BE3750-0F22-47C1-BE0C-B849D838047B Q30316598-C68E1B4C-9ABA-4586-BA80-5A845AB61670 Q30408712-13A1AECC-7B21-42F7-A314-6CD1CCAE2A90 Q34552966-E9BC1CD0-5499-4B0A-9633-F55BC03E34FD Q34596313-2F34B74F-3512-4BFC-B6A8-97D54508DAE7 Q34894900-6DF63C84-D2A5-4ECF-8466-5563B6F7F9FD Q35076958-B7E76F66-302C-414D-A52E-56F1B4555151 Q35860004-BEE93E14-27E6-4FB0-8473-5125FF98A836 Q35942407-5DDFFD1A-62DC-4611-907B-FB42FE612469 Q36072500-5B03BFD0-FECE-4378-9E90-30DB8C2B2FC3 Q36075930-54DCD40D-9E04-4EEA-B905-0A9DD59454AA Q36078359-788F08BD-EFD0-4FFC-8409-EC238F35719F Q36517624-F5872314-5137-477D-A8BE-B49AC14901CA Q36571906-EEDF7734-6024-4867-A888-1EAE11376056 Q36760879-0A398CF3-E801-45CF-B06F-689EC67790AC Q36802059-5024693E-0352-4E48-AD0F-B86ADC801BD9 Q36901488-CC923289-CE0E-47F7-8191-6E9E2BF32F78 Q36970989-F9D8AAAE-ECF0-4C30-956C-42D7E8E464EF Q37167673-3BDBA78E-C849-43B6-8662-A3A304293BDA Q37203803-BC94800A-1FD0-4339-BF68-72B36D0DBA95 Q37538602-AC0E9F36-7DD8-4988-9919-C0DAE194D70D Q37538748-0DDE6A5D-A5B8-4CF4-8A3A-5A3BED561484 Q37612946-CDF1FAF3-9E11-45DC-B1F3-94B338881F90 Q37686607-CF146A66-AEC7-4B9B-8C4A-31AF7C46E098 Q38249103-5FAFE2AF-1A4F-4CA7-9486-D7E8824F5858 Q38271318-15D258EA-A637-422D-9544-39E0A34860D0 Q38364464-19C4C768-9F48-4004-8A4D-16471E40FE39 Q38384662-3579D4BD-3CB0-4658-91C6-5408D8963F93 Q38462784-DA629577-22C5-4380-B68C-33001C7630C8 Q38511551-F25FDEAE-B5A7-42D7-85B3-56200982424F Q38536299-18458991-09C0-4AE1-BF08-AD5E769569EE Q38625059-F1D9173B-0C6C-4297-A692-1B6EC23C498B

P2860

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

http://www.wikidata.org/entity/Q34274190

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Individualised antibiotic dosi ...... enges and potential solutions.

@ast

Individualised antibiotic dosi ...... enges and potential solutions.

@en

Individualised antibiotic dosi ...... enges and potential solutions.

@nl

type

label

Individualised antibiotic dosi ...... enges and potential solutions.

@ast

Individualised antibiotic dosi ...... enges and potential solutions.

@en

Individualised antibiotic dosi ...... enges and potential solutions.

@nl

prefLabel

Individualised antibiotic dosi ...... enges and potential solutions.

@ast

Individualised antibiotic dosi ...... enges and potential solutions.

@en

Individualised antibiotic dosi ...... enges and potential solutions.

@nl

P1433

Q34274190-925AB3C3-B9F3-445F-B13A-32E599681A50

P1476

Q34274190-4C5C954F-A7E2-4E69-B65E-AEA6FEF09375

P2093

Q34274190-0AD8F7C4-882D-468D-8FFD-C348640F8508

Q34274190-0BC4D174-8F47-478F-A603-D987838AD71C

Q34274190-0EAF23F9-DFD3-44C1-8C34-0CC5E50E250F

Q34274190-56D5B804-2F64-48A4-A33E-5E944ED4BA88

Q34274190-5F611118-D861-4B75-A74B-4170A4E7E94F

Q34274190-774133E7-800E-4D0D-8A95-5633C386FF11

Q34274190-9FC58D34-D015-4615-8E63-773C59914287

Q34274190-B962A6E2-7545-482F-89FC-6C1BDBF4F594

Q34274190-D11B0A97-E2AF-4DE8-B972-B3C1D609FD66

Q34274190-EE4FB629-B4D7-48F9-9954-67B4B24B5EC8

P2860

Q34274190-037926C0-644D-49AC-9954-001B314BA52F

Q34274190-03F7353D-5B63-41C8-A8DF-86F6C1268EFF

Q34274190-0496C5AD-51B7-488B-9B96-CEBFCCDED88B

Q34274190-0BB253BC-2A0D-4D56-8D87-73EC16EAFABE

Q34274190-0C068E8A-2A9A-4FB6-A940-5FA64CA147A6

Q34274190-0D934788-D836-4B16-88B3-16482635B8AE

Q34274190-0DA83B41-C42A-4EFB-9CCF-877B255B7C49

Q34274190-13B06316-02DC-4661-9C56-43018DD60BBD

Q34274190-13DE430B-B14D-4D23-98B6-92C6F9321426

Q34274190-14FF34A3-BBFA-40AC-A27E-65673E347FA4

P304

Q34274190-886B9762-B12F-4B4A-A956-4D89BB1AA0C0

P31

Q34274190-160D70FD-3E3F-461A-8028-CC5E52123895

P356

Q34274190-9747C80A-D267-4793-BDDD-149D267118A1

P433

Q34274190-31183921-5400-475A-BBF8-A7FA629F1BB5

P478

Q34274190-E17D6AD5-30FC-432F-BCC6-0640CAF2C843

P50

Q34274190-7DA541FB-35AD-44C6-8254-06E21034637D

Q34274190-7E98D734-5836-45BC-B980-8C6B88CF2ADD

Q34274190-C9A5730A-D94E-4D9C-8D3B-1539B88F549F

Q34274190-E35BBC42-B4C8-4B42-BFCE-6F2658386153

Q34274190-EE64D32B-E042-4565-B534-559A3EEBD81F

P577

Q34274190-3A0DE8A1-6D99-4D43-BF49-9400FEDEA3EC

P698

Q34274190-CE503DF2-E0AB-445C-B83F-0E50C0AAF0C4

P921

Q34274190-83F9F7C6-C50C-4C5A-BEEC-BC6C9665AD3B

Q34274190-93EDE9AA-0BB7-4937-94F7-A10A2B46BCA7

P932

Q34274190-27291B4C-63C2-4D9A-B82F-529885C8DC43

P356

S1473-3099(14)70036-2

P1433

The Lancet Infectious Diseases

P1476

Individualised antibiotic dosi ...... enges and potential solutions.

@en

P2093

Alexander A Vinks

http://www.w3.org/2001/XMLSchema#string

Andras Farkas

http://www.w3.org/2001/XMLSchema#string

George Drusano

http://www.w3.org/2001/XMLSchema#string

International Society of Anti- ...... iology and Infectious Diseases

http://www.w3.org/2001/XMLSchema#string

Jerome J Schentag

http://www.w3.org/2001/XMLSchema#string

Johan W Mouton

http://www.w3.org/2001/XMLSchema#string

Joseph L Kuti

http://www.w3.org/2001/XMLSchema#string

Michael N Neely

http://www.w3.org/2001/XMLSchema#string

Otto R Frey

http://www.w3.org/2001/XMLSchema#string

Ursula Theuretzbacher

http://www.w3.org/2001/XMLSchema#string

P2860

A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

P304

498-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1473-3099(14)70036-2

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Jason A. Roberts

Mohd-Hafiz Abdul-Aziz

P577

2014-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24768475

http://www.w3.org/2001/XMLSchema#string

P921

P932

4181663

http://www.w3.org/2001/XMLSchema#string